1.68
price up icon1.20%   0.02
after-market アフターアワーズ: 1.68
loading
前日終値:
$1.66
開ける:
$1.675
24時間の取引高:
9.94M
Relative Volume:
3.81
時価総額:
$191.34M
収益:
$13.45M
当期純損益:
$-178.23M
株価収益率:
-0.7742
EPS:
-2.17
ネットキャッシュフロー:
$-132.53M
1週間 パフォーマンス:
-8.20%
1か月 パフォーマンス:
-24.32%
6か月 パフォーマンス:
-53.20%
1年 パフォーマンス:
-45.10%
1日の値動き範囲:
Value
$1.6404
$1.80
1週間の範囲:
Value
$1.59
$2.065
52週間の値動き範囲:
Value
$1.59
$8.83

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
名前
Fate Therapeutics Inc
Name
セクター
Healthcare (1176)
Name
電話
858.875.1803
Name
住所
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
職員
181
Name
Twitter
@fatethx
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
FATE's Discussions on Twitter

FATE を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
FATE
Fate Therapeutics Inc
1.68 191.34M 13.45M -178.23M -132.53M -1.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-11-18 アップグレード BofA Securities Underperform → Neutral
2024-06-17 アップグレード Piper Sandler Neutral → Overweight
2023-03-27 再開されました Wells Fargo Equal Weight
2023-01-24 ダウングレード H.C. Wainwright Buy → Neutral
2023-01-06 ダウングレード BMO Capital Markets Outperform → Market Perform
2023-01-06 ダウングレード BofA Securities Buy → Underperform
2023-01-06 ダウングレード Cowen Outperform → Market Perform
2023-01-06 ダウングレード Piper Sandler Overweight → Neutral
2023-01-06 ダウングレード Stifel Buy → Hold
2023-01-06 ダウングレード Truist Buy → Hold
2023-01-06 ダウングレード Wedbush Outperform → Neutral
2023-01-03 ダウングレード Guggenheim Buy → Neutral
2022-12-22 ダウングレード Oppenheimer Outperform → Perform
2022-12-15 開始されました Goldman Sell
2022-11-04 再開されました Cantor Fitzgerald Overweight
2022-10-10 開始されました Canaccord Genuity Buy
2022-08-18 再開されました Wells Fargo Overweight
2022-07-28 開始されました Needham Hold
2022-07-11 アップグレード BMO Capital Markets Market Perform → Outperform
2022-06-03 開始されました Robert W. Baird Neutral
2022-02-11 再開されました BMO Capital Markets Market Perform
2021-12-15 アップグレード Wedbush Neutral → Outperform
2021-12-07 開始されました Cowen Outperform
2021-11-09 アップグレード Citigroup Neutral → Buy
2021-08-26 開始されました Morgan Stanley Equal-Weight
2021-06-07 アップグレード H.C. Wainwright Neutral → Buy
2021-05-07 アップグレード Wedbush Neutral → Outperform
2021-04-26 再開されました Jefferies Buy
2021-02-26 開始されました BofA Securities Buy
2021-02-26 ダウングレード Wedbush Outperform → Neutral
2021-02-11 ダウングレード Citigroup Buy → Neutral
2021-01-27 再開されました H.C. Wainwright Neutral
2020-05-13 開始されました H.C. Wainwright Buy
2020-03-04 開始されました Barclays Overweight
2020-01-09 ダウングレード BMO Capital Markets Outperform → Market Perform
2019-12-30 繰り返されました Mizuho Buy
2019-12-09 アップグレード Wells Fargo Market Perform → Outperform
2019-11-12 開始されました SunTrust Buy
2019-11-06 ダウングレード Wells Fargo Outperform → Market Perform
2019-10-01 開始されました Stifel Buy
2019-08-09 開始されました BTIG Research Buy
2019-07-22 開始されました Cantor Fitzgerald Overweight
2019-07-12 開始されました Oppenheimer Outperform
2019-06-13 開始されました Mizuho Buy
2019-06-07 開始されました ROTH Capital Neutral
2019-05-31 開始されました Guggenheim Buy
2019-05-24 再開されました Citigroup Buy
2019-03-28 開始されました SVB Leerink Outperform
2019-01-03 ダウングレード Stephens Overweight → Equal-Weight
2018-11-05 開始されました Jefferies Buy
2018-08-01 開始されました Citigroup Buy
2018-03-06 ダウングレード H.C. Wainwright Buy → Neutral
すべてを表示

Fate Therapeutics Inc (FATE) 最新ニュース

pulisher
Dec 19, 2024

Critical Survey: Fate Therapeutics (NASDAQ:FATE) versus HilleVax (NASDAQ:HLVX) - Defense World

Dec 19, 2024
pulisher
Dec 18, 2024

Fmr LLC Buys 46,892 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Dec 18, 2024
pulisher
Dec 17, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Sees Significant Growth in Short Interest - MarketBeat

Dec 17, 2024
pulisher
Dec 16, 2024

FATE LAWSUIT ALERT: Levi & Korsinsky Notifies Fate Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Marketscreener.com

Dec 16, 2024
pulisher
Dec 15, 2024

Fate Therapeutics' SWOT analysis: cell therapy stock shows promise amid risks - Investing.com

Dec 15, 2024
pulisher
Dec 15, 2024

Fate Therapeutics' SWOT analysis: cell therapy stock shows promise amid risks By Investing.com - Investing.com South Africa

Dec 15, 2024
pulisher
Dec 13, 2024

BNP Paribas Financial Markets Raises Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Dec 13, 2024
pulisher
Dec 12, 2024

Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Dec 12, 2024
pulisher
Dec 12, 2024

FATE stock touches 52-week low at $1.96 amid market challenges - Investing.com

Dec 12, 2024
pulisher
Dec 12, 2024

FATE stock touches 52-week low at $1.96 amid market challenges By Investing.com - Investing.com South Africa

Dec 12, 2024
pulisher
Dec 09, 2024

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus - The Manila Times

Dec 09, 2024
pulisher
Dec 09, 2024

Fate Therapeutics Presents New Phase 1 Clinical Data of - GlobeNewswire

Dec 09, 2024
pulisher
Dec 09, 2024

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for - EIN News

Dec 09, 2024
pulisher
Dec 09, 2024

Fate Therapeutics' Off-the-Shelf CAR T Shows Breakthrough Results in Lupus TreatmentPhase 1 Data - StockTitan

Dec 09, 2024
pulisher
Dec 03, 2024

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Dec 03, 2024
pulisher
Dec 03, 2024

Fate Therapeutics makes Bob Valamehr president and CEO - MSN

Dec 03, 2024
pulisher
Dec 03, 2024

Brokerages Set Fate Therapeutics, Inc. (NASDAQ:FATE) PT at $6.75 - MarketBeat

Dec 03, 2024
pulisher
Dec 03, 2024

Bob Valamehr to succeed CEO Scott Wolchko at Fate - BioCentury

Dec 03, 2024
pulisher
Nov 30, 2024

Fate Therapeutics appoints new CEO as Wolchko retires By Investing.com - Investing.com Australia

Nov 30, 2024
pulisher
Nov 29, 2024

Fate Therapeutics Announces Leadership Transition for 2025 - TipRanks

Nov 29, 2024
pulisher
Nov 29, 2024

Fate Therapeutics Taps Bob Valamehr to Be CEO - MarketWatch

Nov 29, 2024
pulisher
Nov 29, 2024

Fate Therapeutics Announces Leadership Transition - The Manila Times

Nov 29, 2024
pulisher
Nov 29, 2024

Fate Therapeutics appoints new CEO as Wolchko retires - Investing.com

Nov 29, 2024
pulisher
Nov 29, 2024

Fate Therapeutics, Inc. Announces President Changes - Marketscreener.com

Nov 29, 2024
pulisher
Nov 29, 2024

Vestal Point Capital LP Sells 315,000 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat

Nov 29, 2024
pulisher
Nov 29, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Sees Large Drop in Short Interest - MarketBeat

Nov 29, 2024
pulisher
Nov 26, 2024

Fate Therapeutics to Present at Upcoming December Investor Conferences - The Manila Times

Nov 26, 2024
pulisher
Nov 23, 2024

Fate Therapeutics (NASDAQ:FATE) Given Hold Rating at Needham & Company LLC - Defense World

Nov 23, 2024
pulisher
Nov 21, 2024

Fate Therapeutics' SWOT analysis: clinical progress boosts stock outlook - Investing.com

Nov 21, 2024
pulisher
Nov 21, 2024

Fate Therapeutics' SWOT analysis: clinical progress boosts stock outlook By Investing.com - Investing.com Canada

Nov 21, 2024
pulisher
Nov 20, 2024

FATE Presents Encourgaing Data From Lupus Study, Stock Gains - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options - Seeking Alpha

Nov 20, 2024
pulisher
Nov 20, 2024

Fate stock closes 12% higher after soaring 73% on drug data (update) - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Bank of America Upgrades Fate Therapeutics (NASDAQ:FATE) to Neutral - Defense World

Nov 20, 2024
pulisher
Nov 19, 2024

Needham & Company LLC Reaffirms "Hold" Rating for Fate Therapeutics (NASDAQ:FATE) - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

Fate Thera rockets on early data for FT819 - The Pharma Letter

Nov 19, 2024
pulisher
Nov 18, 2024

Analyst cites quality-of-life improvements while maintaining Hold on Fate Therapeutics stock - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

BofA upgrades Fate Therapeutics to neutral; target to $3 from $3.50 By Investing.com - Investing.com UK

Nov 18, 2024
pulisher
Nov 18, 2024

Stock market today: Fate Therapeutics gains 70.79% whereas SiNtx Technologies rose by 38.73% in early trading - Business Upturn

Nov 18, 2024
pulisher
Nov 18, 2024

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence - The Manila Times

Nov 18, 2024
pulisher
Nov 18, 2024

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence - GlobeNewswire

Nov 18, 2024
pulisher
Nov 18, 2024

Fate Therapeutics (FATE) Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study - StreetInsider.com

Nov 18, 2024
pulisher
Nov 18, 2024

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed - GlobeNewswire

Nov 18, 2024
pulisher
Nov 15, 2024

Wedbush Decreases Earnings Estimates for Fate Therapeutics - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance

Nov 15, 2024
pulisher
Nov 14, 2024

Fate Therapeutics stock hits 52-week low at $2.09 By Investing.com - Investing.com Canada

Nov 14, 2024

Fate Therapeutics Inc (FATE) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
大文字化:     |  ボリューム (24 時間):